论文部分内容阅读
目的分析氨基酸代谢动力学研究中在持续静脉输注标记氨基酸的状态下、不同时间点上标记氨基酸的代谢终产物丰度值的差异及不同蛋白质剂量组标记氨基酸的氧化分解程度。方法20名健康青年男性分为2组,分别进食不同的蛋白质膳食,经过5天适应期后,在第6天经静脉给予13C-亮氨酸3小时,在输注结束前的半小时每隔15分钟收集受试者的呼出气样本,比较3个时间点上呼出气样品中13C的丰度值及2组受试者在输液结束时的13CO2产生率,以确定不同取样时间点上同位素丰度是否处于一个相对稳定的状态及膳食蛋白质摄入量对13CO2产生率影响。结果每组受试者在3个时间点上13C的丰度值之间差异无显著性(P>0.05),0.89g/kg蛋白质剂量组受试者的13CO2产生率高于0.80g/kg蛋白质剂量组受试者的13CO2产生率(P<0.05)。结论稳定同位素示踪技术探讨蛋白质和氨基酸的生理需要量时可以在坪台期上确定一个同一的取样时间点进而比较不同蛋白质和氨基酸剂量组的代谢动力学变化,并且摄入高剂量蛋白质组的氧化分解程度高于低剂量组。
OBJECTIVE: To analyze the differences in the abundance of end products of labeled amino acids and the degree of oxidative degradation of labeled amino acids in different protein dosage groups under continuous intravenous infusion of labeled amino acids in amino acid kinetic studies. Methods Twenty healthy young men were divided into two groups, each of whom received different protein diets. After a 5-day adaptation period, 13C-leucine was intravenously administered on the 6th day for 3 hours, and half an hour before the end of the infusion Fifteen minutes of exhaled breath samples were collected subjects to compare the three time points on the exhaled breath samples 13C abundance values and two subjects at the end of infusion 13CO2 production rate to determine the different sampling time points isotope abundance Degree is in a relatively stable state and dietary protein intake on 13CO2 production rate. Results There was no significant difference in the 13C abundance between the three time points (P> 0.05). The rate of 13CO2 production in the 0.89 g / kg protein dose group was higher than that of the 0.80 g / kg protein The rate of 13CO2 production in the dose group subjects (P <0.05). Conclusions Stable isotope tracing technique is used to determine the physiological requirements for proteins and amino acids to determine the same sampling time point on the plateau phase to compare the changes in the metabolic dynamics of different protein and amino acid dose groups and to ingest the high dose proteome The degree of oxidative decomposition is higher than the low dose group.